Combined Levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma a phase II study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 2, 1998, Pages 139-141

  Creagan, Edward T ^a   Hestorff, Robert D ^b   Suman, Vera J ^a   Mailliard, James A ^c   Nair, Suresh ^d   Krook, James E ^e   Kugler, John W ^f   Marschke Jr , Robert F ^g   Michalak, John C ^h   Tschetter, Loren K ⁱ  

^a MAYO CLINIC   (United States)

^b Grand Forks Clinic   (United States)

^c Missouri Valley CCOP   (United States)

^d GEISINGER MEDICAL CENTER   (United States)

^e Duluth Community Clinical Oncology Program   (United States)

^f Illinois Oncol Res Assoc CCOP   (United States)

^g MAYO CLINIC   (United States)

^h Siouxland Hematology Oncology Associates   (United States)

ⁱ Sioux Community Cancer Consortium   (United States)

Author keywords

Interleukin 2; Renal cell cancer

Indexed keywords

INTERLEUKIN 2; LEVAMISOLE;

ADOPTIVE IMMUNOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; FEMALE; GROWTH INHIBITION; HUMAN; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; TUMOR GROWTH;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; LEVAMISOLE; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS;

EID: 0031899690     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199804000-00008     Document Type: Article

References (5)

1. van Haelst-Pisani CM, Pisani RJ, Kovach JS. Cancer immuno-therapy: Current status of treatment with interleukin-2 and lymphokine-activated killer cells. Mayo Clin Proc 1989;64:451-65.
2. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313(23):1485-92.
3. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and IL-2 or high-dose IL-2 alone. N Engl J Med 1987;316(15):889-97.
4. Redondo JM, Lopez-Guerrero JA, Fresno M. Potentiation of IL-2 activity by levamisole and imidazole. Immunol Lett 1986/1987;14:111-6.
5. Creagan ET, Rowland KM, Suman VJ, Kardinal CG, Marschke RF Jr, Marks RS, Maples WJ. Phase II study of combined levamisole with recombinant interleukin-2 in patients with advanced malignant melanoma. Am J Clin Oncol 1997;20:490-2.